1. Scrip
  2. >>Business
  3. >>Financing

Ascentage Grosses $126.4m In First Biopharma IPO In The US For 2025

 
• By Joseph Haas

The China/US hematologic cancer-focused firm said the offering should give it runway into 2028, perhaps time enough to bring its top two pipeline assets to market in the US.

IPO
Ascentage lands the first biopharma IPO of 2025 • Source: Shutterstock

Maryland- and Suzhou, China-headquartered Ascentage Pharma became the first biopharmaceutical firm to complete an initial public offering in the US in 2025, pricing 7.33 million American depositary shares (ADSs) at $17.25 each to gross $126.4m on 24 January. Partnered with Takeda on lead asset olverembatinib for chronic myeloid leukemia (CML), Ascentage said the funds should give it financial runway into 2028 for its pipeline of small molecules in hematologic cancers.

Key Takeaways
  • Already publicly traded in Hong Kong, Ascentage raised $126.4m in its 24 January IPO, making it the first biopharma company to go public in the US in 2025.

Ascentage already trades on the Hong Kong stock exchange, but chairman and CEO Dahun Yang told Scrip that his company,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

BeBetter, Trinomab Advance IPOs On China’s STAR Market In Firsts Since Policy Easing

 
• By Dexter Jie Yan

BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

Finance Watch: Just As The XBI Began Turnaround, Trump Upped MFN Pricing Threats

 
• By Mandy Jackson

Public Company Edition: The XBI fund attempted a correction midway through the week ending Aug. 1, but President Trump’s most favored nation drug pricing threats tanked valuations again. In financings, Leads Biolabs raised $189m in a Hong Kong IPO and Abivax closed a $747.5m FOPO.

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

More from Focus On Asia

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.